Akebia Therapeutics, Inc. AKBA

New director brings nephrology development expertise and over 30 years of experience in the biopharmaceutical industryJERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Steven K. Burke, M.D., to its Board of Directors, effective September 18, 2026. Dr. Burke brings more than 30 years of indu

Experienced biopharmaceutical and nephrology leader joins SCYNEXIS to advance its rare disease development programsJERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Todd Minga, M.D. as Senior Vice President, Research & Development, effective September 14, 2026. Dr. Minga brings more than two de

Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the first patient has been dosed in its Phase 2 basket trial evaluating ebribafusp for the treatment of rare complement-mediat

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 8,400 shares of Akebia’s common stock on August 31, 2026. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, which will take place in Boston, September 8 – 10, 2026. During meetings, management will disc

Akebia Therapeutics Inc (AKBA) reports strong Vafseo growth with over 10,500 patients, while navigating Erixia declines and planning strategic price adjustments for 2027.

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +33.33% and -5.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million; more than 10,500 patients now on therapy Advancement of rare kidney disease pipeline continues with initiation of Phase 2 open-label basket trial evaluating ebribafusp for treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy; initial data expected in 2027 Interim analysis of VOICE trial demonstrated overwhelming statistical evidence of improved safety outcomes for patients treated with Vafseo versus an ESA Ak

The open-label Phase 2 trial will evaluate ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathyCAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a Phase 2 basket trial to evaluate the safety, efficacy, and pharmacokinetics of ebribafusp for the treatment of rare complement-mediated k

Akebia to Host Conference Call on August 5 at 4:30 p.m. EDTCAMBRIDGE, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2026 on Wednesday, August 5, 2026, following the close of the financial markets. Akebia will host a conference call on Wednesday, August 5, 2026, at 4:30 p.m. EDT to discuss its financial results and recent business highlights. To access the call, please

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best low-priced pharma stocks on this list. TheFly reported on June 10 that AKBA strengthened the intellectual property protection for its flagship therapy, Vafseo (vadadustat), after receiving a new patent listing in the […]

Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation from Independent Data Monitoring Committee and Trial Steering Committee Interim analysis on primary endpoint replicated safety outcomes reported in the recently published win odds analysis of the INNO2VATE clinical trial program Akebia and USRC expect to submit data for presentation at an upcoming

Additional Orange Book Listed Patent Secured and Composition of Matter Patent is Eligible for 5-Year ExtensionCAMBRIDGE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that a new patent has been granted and listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) and it has been notified of eligibility to ex

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY. A live webcast of the presentation can be accessed through th